Report of Foreign Issuer (6-k)
August 03 2017 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For the
month of
August
2017
Commission
File Number
001-16174
TEVA PHARMACEUTICAL INDUSTRIES
LIMITED
(Translation
of registrant’s name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
(Address
of principal executive offices)
Indicate by
check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
⃞
CONTENTS
This Report on Form 6-K consists of the following document, which is
attached hereto and incorporated by reference herein:
99.1
|
|
Press Release: Teva Reports Second Quarter 2017 Financial Results
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
|
|
|
|
|
|
Date: August 3, 2017
|
By:
|
/S/ MICHAEL MCCLELLAN
|
|
Name:
|
Michael McClellan
|
|
Title:
|
Interim Chief Financial Officer
|
2
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024